OBN BioTuesday: A Spotlight on Oncology Precision Prevention Treatments and the Expected Impact on People with High-Risk Conditions

This edition of our ever popular BioTuesday event will provide 'OBN BioTuesday: A Spotlight on Oncology Precision Prevention Treatments and the Expected Impact on People with High-Risk Conditions'


About the event

Speakers on the night will share insight on the new era of cancer prevention trials. Research and clinical trials in cancer prevention are critical for improving patient outcomes and reducing pressure on healthcare systems. The new field of precision prevention exploits biological insights into risk factors and cancer development to precisely target interventions to individuals at high risk, with the aim of delaying or preventing cancer. Oxford University hosts the UK's first and only Cancer Research UK-accredited trials centre specialising in cancer precision prevention studies and is changing the way that these trials are run. Compared to traditional cancer prevention trials, precision prevention trials are more focused, smaller and shorter, and thus more attractive to commercial timelines. This event will highlight the innovations in cancer prevention trials and explore the impact on pharma and people affected by a high-risk condition.


Outline Programme:

17:00 – 17:30 - Registration & networking

17:30 – 19:00 – Presentations & discussions:

30-minute scene setting keynote, Prof Sarah Blagden

60-minute chaired discussion with speakers representing Big Pharma, Small Pharma, Regulatory expert, Patient, to include 5-minute stand-alone intro from each speaker and audience questions. Contributors include:

19:00 – 20:00 – Networking, drinks & nibbles



Speakers

  • Sarah Blagden (Professor of Medical Oncology, Director of OCTO at University of Oxford)

    Sarah Blagden

    Professor of Medical Oncology, Director of OCTO at University of Oxford

    Following medical training, Sarah undertook subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, London. Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship to study fruit fly genetics at Cambridge University (2000-2004) and later held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.

    She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and established her laboratory studying the dysregulation of mRNA translation in cancer. In 2015 she moved to Oxford University as an Associate Professor of Experimental Oncology and was director of the Early Phase Clinical Trials Unit until 2021. She is Oxford's ECMC lead and runs a research group in the Old Road Campus Research Building. In July 2021, Sarah took over leadership of the Oxford Clinical Trials Office (OCTO). She has been chief or principal investigator for a number of national and international clinical studies, is involved in cancer prevention and early diagnosis and her research focus is post-transcriptional gene regulation in ovarian cancer.

    view more
  • Anna Fry (PPI Representative)

    Anna Fry

    PPI Representative

    Anna Fry is a Patient and Public Involvement (PPI) representative on a group exploring cancer prevention strategies for people at high risk. Anna has Lynch Syndrome – a genetic predisposition to developing certain cancers. It’s estimated 1 in 400 people have Lynch Syndrome (around 175,000 people in England) but only 5% of those people (“Lynchies”) are aware. Anna works in the field of cancer research but is here as a patient representative.

    view more
  • Catherine Pollard (Senior Director Strategic Operations UK, Clinical Development of Moderna)

    Catherine Pollard

    Senior Director Strategic Operations UK, Clinical Development of Moderna

    As the Senior Director for Strategic Operations, Catherine oversees Moderna’s significant investment into R&D activities and the expansion of our clinical trial footprint across the UK, Canada and Australia.

    Catherine joined Moderna in October 2022 from the NHS, where she has spent over 12 years in a range of strategy, policy and transformation roles – national and local. Most recently she was Director of Technology Policy for NHS England and the Department of Health & Social Care, including developing plans to harness NHS data for research and innovation.

    view more
  • Kirsty Wydenbach (Head of Reguatory Strategy at Weatherden)

    Kirsty Wydenbach

    Head of Reguatory Strategy at Weatherden

    Dr Kirsty Wydenbach has been the Head of Regulatory Strategy at Weatherden, a global integrated consultancy, since 2022. Previously she has over 13 years’ experience as an Expert Medical Assessor at MHRA within the Clinical Trials Unit. Kirsty was involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-human studies. She also currently chairs the Clinical Trial Science and Regulations Expert Group of the Faculty of Pharmaceutical Medicine and is a visiting lecturer for King’s College London.

    view more

Venue

BioEscalator

Innovation Building
Old Road Campus
Roosevelt Drive
OX3 7FZ

Oxford, United Kingdom

If you have any questions please contact

Contact Organizer

Show on map

Tickets

OBN Member - Complimentary Ticket
Member Price Complimentary
Non-OBN Member Ticket
Standard Price £50
Academics, BioEscalator Tenants & Research Scientists - Complimentary Ticket
Standard Price Complimentary
Speaker
Standard Price Complimentary